Report Update Mar 1, 2026

Czech Republic - Medicaments of Penicillins, Streptomycins or Derivatives Thereof - Market Analysis, Forecast, Size, Trends and Insights

Single report

Sent by email within 24h (Mon-Fri)

$599 Basic Edition

$2095 Professional Edition

What's the difference?

Subscription

Online access and download

from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing

Czech Republic: Market for Medicaments Of Penicillins, Streptomycins Or Derivatives Thereof 2026

Market Size for Medicaments Of Penicillins, Streptomycins Or Derivatives Thereof in the Czech Republic

In 2025, the Czech penicillins or streptomycins medicaments market increased by X% to $X, rising for the second consecutive year after two years of decline. Over the period under review, consumption, however, showed a noticeable downturn. Penicillins or streptomycins medicaments consumption peaked at $X in 2013; however, from 2014 to 2025, consumption remained at a lower figure.

Exports of Medicaments Of Penicillins, Streptomycins Or Derivatives Thereof

Exports from the Czech Republic

Penicillins or streptomycins medicaments exports from the Czech Republic dropped to X tons in 2025, with a decrease of X% against the previous year's figure. Over the period under review, exports, however, saw a resilient expansion. The pace of growth was the most pronounced in 2014 when exports increased by X% against the previous year. The exports peaked at X tons in 2015; however, from 2016 to 2025, the exports failed to regain momentum.

In value terms, penicillins or streptomycins medicaments exports rose remarkably to $X in 2025. Overall, exports, however, enjoyed a tangible increase. The most prominent rate of growth was recorded in 2019 with an increase of X% against the previous year. The exports peaked in 2025 and are likely to see steady growth in the immediate term.

Exports by Country

Slovakia (X tons) was the main destination for penicillins or streptomycins medicaments exports from the Czech Republic, accounting for a X% share of total exports. Moreover, penicillins or streptomycins medicaments exports to Slovakia exceeded the volume sent to the second major destination, Ukraine (X tons), fourfold. The third position in this ranking was taken by Lithuania (X tons), with a X% share.

From 2012 to 2025, the average annual rate of growth in terms of volume to Slovakia amounted to X%. Exports to the other major destinations recorded the following average annual rates of exports growth: Ukraine (X% per year) and Lithuania (X% per year).

In value terms, Slovakia ($X) remains the key foreign market for medicaments of penicillins, streptomycins or derivatives thereof exports from the Czech Republic, comprising X% of total exports. The second position in the ranking was held by Denmark ($X), with a X% share of total exports. It was followed by Ukraine, with a X% share.

From 2012 to 2025, the average annual rate of growth in terms of value to Slovakia totaled X%. Exports to the other major destinations recorded the following average annual rates of exports growth: Denmark (X% per year) and Ukraine (X% per year).

Export Prices by Country

In 2025, the average penicillins or streptomycins medicaments export price amounted to $X per ton, surging by X% against the previous year. Over the period under review, the export price, however, showed a pronounced curtailment. The most prominent rate of growth was recorded in 2017 an increase of X% against the previous year. Over the period under review, the average export prices hit record highs at $X per ton in 2012; however, from 2013 to 2025, the export prices remained at a lower figure.

Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was Denmark ($X per ton), while the average price for exports to the Philippines ($X per ton) was amongst the lowest.

From 2012 to 2025, the most notable rate of growth in terms of prices was recorded for supplies to Romania (X%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Of Penicillins, Streptomycins Or Derivatives Thereof

Imports into the Czech Republic

For the third consecutive year, the Czech Republic recorded growth in supplies from abroad of medicaments of penicillins, streptomycins or derivatives thereof, which increased by X% to X tons in 2025. The total import volume increased at an average annual rate of X% from 2012 to 2025; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The pace of growth was the most pronounced in 2023 when imports increased by X% against the previous year. Over the period under review, imports reached the maximum in 2025 and are expected to retain growth in the immediate term.

In value terms, penicillins or streptomycins medicaments imports fell to $X in 2025. Overall, imports, however, recorded a pronounced shrinkage. The most prominent rate of growth was recorded in 2023 when imports increased by X% against the previous year. Over the period under review, imports attained the maximum at $X in 2012; however, from 2013 to 2025, imports remained at a lower figure.

Imports by Country

Austria (X tons), Portugal (X tons) and Slovakia (X tons) were the main suppliers of penicillins or streptomycins medicaments imports to the Czech Republic, with a combined X% share of total imports. Italy, the UK, Belgium, Poland, Cyprus, Germany, France, Slovenia and India lagged somewhat behind, together accounting for a further X%.

From 2012 to 2025, the biggest increases were recorded for Belgium (with a CAGR of X%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, Slovakia ($X), Austria ($X) and Portugal ($X) constituted the largest penicillins or streptomycins medicaments suppliers to the Czech Republic, together accounting for X% of total imports. Italy, Poland, Germany, the UK, Belgium, Cyprus, Slovenia, France and India lagged somewhat behind, together accounting for a further X%.

In terms of the main suppliers, Belgium, with a CAGR of X%, saw the highest growth rate of the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The average penicillins or streptomycins medicaments import price stood at $X per ton in 2025, which is down by X% against the previous year. Overall, the import price recorded a abrupt decline. The pace of growth was the most pronounced in 2023 an increase of X%. The import price peaked at $X per ton in 2012; however, from 2013 to 2025, import prices failed to regain momentum.

There were significant differences in the average prices amongst the major supplying countries. In 2025, amid the top importers, the country with the highest price was Slovenia ($X per ton), while the price for Austria ($X per ton) was amongst the lowest.

From 2012 to 2025, the most notable rate of growth in terms of prices was attained by Slovenia (X%), while the prices for the other major suppliers experienced more modest paces of growth.

Frequently Asked Questions (FAQ) :

What are the largest markets for medicaments of penicillins, streptomycins or derivatives thereof in the world?

The countries with the highest volumes of consumption in 2024 were China, Turkey and the United States, with a combined 37% share of global consumption.

What are the largest producers of medicaments of penicillins, streptomycins or derivatives thereof in the world?

The countries with the highest volumes of production in 2024 were China, India and Turkey, with a combined 47% share of global production.

What are the leading suppliers of medicaments of penicillins, streptomycins or derivatives thereof to the Czech Republic?

In value terms, the largest penicillins or streptomycins medicaments suppliers to the Czech Republic were Slovakia, Austria and Portugal, with a combined 52% share of total imports. Italy, Poland, Germany, the UK, Belgium, Cyprus, Slovenia, France and India lagged somewhat behind, together accounting for a further 44%.

What are the leading importers of medicaments of penicillins, streptomycins or derivatives thereof from the Czech Republic?

In value terms, Slovakia remains the key foreign market for medicaments of penicillins, streptomycins or derivatives thereof exports from the Czech Republic, comprising 59% of total exports. The second position in the ranking was held by Denmark, with a 15% share of total exports. It was followed by Ukraine, with a 4.9% share.

What is the average export price for medicaments of penicillins, streptomycins or derivatives thereof in the Czech Republic?

The average penicillins or streptomycins medicaments export price stood at $97,358 per ton in 2024, surging by 12% against the previous year. In general, the export price, however, recorded a perceptible setback. The most prominent rate of growth was recorded in 2017 an increase of 165%. Over the period under review, the average export prices hit record highs at $165,239 per ton in 2012; however, from 2013 to 2024, the export prices stood at a somewhat lower figure.

What is the average import price for medicaments of penicillins, streptomycins or derivatives thereof in the Czech Republic?

In 2024, the average penicillins or streptomycins medicaments import price amounted to $57,248 per ton, with a decrease of -17.5% against the previous year. In general, the import price continues to indicate a abrupt decrease. The most prominent rate of growth was recorded in 2023 when the average import price increased by 35% against the previous year. Over the period under review, average import prices hit record highs at $131,292 per ton in 2012; however, from 2013 to 2024, import prices failed to regain momentum.

This report provides a comprehensive view of the penicillins or streptomycins medicaments industry in the Czech Republic, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the penicillins or streptomycins medicaments landscape in the Czech Republic.

Key findings

Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
Supply depends on input availability and production efficiency, creating a distinct national cost curve.
Market concentration varies by segment, creating different competitive landscapes and entry barriers.
The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for the Czech Republic. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

Market size and growth in value and volume terms
Consumption structure by end-use segments
Production capacity, output, and cost dynamics
Trade flows, exporters, importers, and balances
Price benchmarks, unit values, and margin signals
Competitive context and market entry conditions

Product coverage

Prodcom 21201160 - Medicaments of penicillins, streptomycins or derivatives thereof, in doses or p.r.s.

Country coverage

Czech Republic

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for the Czech Republic. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

International trade data (exports, imports, and mirror statistics)
National production and consumption statistics
Company-level information from financial filings and public releases
Price series and unit value benchmarks
Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links penicillins or streptomycins medicaments demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in the Czech Republic.

Historical baseline: 2012-2025
Forecast horizon: 2026-2035
Scenario-based sensitivity to income growth, substitution, and regulation
Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

Price benchmarks by country and sub-region
Export and import unit value trends
Seasonality and calendar effects in trade flows
Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

Business focus and production capabilities
Geographic reach and distribution networks
Cost structure and pricing strategy indicators
Compliance, certification, and sustainability context

How to use this report

Quantify domestic demand and identify the most attractive segments
Evaluate export opportunities and prioritize target destinations
Track price dynamics and protect margins
Benchmark performance against leading competitors
Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of penicillins or streptomycins medicaments dynamics in the Czech Republic.

FAQ

What is included in the penicillins or streptomycins medicaments market in the Czech Republic?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for the Czech Republic.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. INTRODUCTION

Making Data-Driven Decisions to Grow Your Business
1. REPORT DESCRIPTION
2. RESEARCH METHODOLOGY AND THE AI PLATFORM
3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
4. GLOSSARY AND SPECIFIC TERMS
2. EXECUTIVE SUMMARY

A Quick Overview of Market Performance
1. KEY FINDINGS
2. MARKET TRENDSThis Chapter is Available Only for the Professional EditionPRO
3. MARKET OVERVIEW

Understanding the Current State of The Market and its Prospects
1. MARKET SIZE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. MARKET STRUCTURE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
3. TRADE BALANCE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
4. PER CAPITA CONSUMPTION: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
5. MARKET FORECAST TO 2035
4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

Finding New Products to Diversify Your Business
- This Chapter is Available Only for the Professional EditionPRO
1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
2. BEST-SELLING PRODUCTS
3. MOST CONSUMED PRODUCTS
4. MOST TRADED PRODUCTS
5. MOST PROFITABLE PRODUCTS FOR EXPORTS
5. MOST PROMISING SUPPLYING COUNTRIES

Choosing the Best Countries to Establish Your Sustainable Supply Chain
- This Chapter is Available Only for the Professional EditionPRO
1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
2. TOP PRODUCING COUNTRIES
3. TOP EXPORTING COUNTRIES
4. LOW-COST EXPORTING COUNTRIES
6. MOST PROMISING OVERSEAS MARKETS

Choosing the Best Countries to Boost Your Export
- This Chapter is Available Only for the Professional EditionPRO
1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
2. TOP CONSUMING MARKETS
3. UNSATURATED MARKETS
4. TOP IMPORTING MARKETS
5. MOST PROFITABLE MARKETS
7. PRODUCTION

The Latest Trends and Insights into The Industry
1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
8. IMPORTS

The Largest Import Supplying Countries
1. IMPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)
9. EXPORTS

The Largest Destinations for Exports
1. EXPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)
10. PROFILES OF MAJOR PRODUCERS

The Largest Producers on The Market and Their Profiles
- This Chapter is Available Only for the Professional EditionPRO
LIST OF TABLES
1. Key Findings In 2025
2. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
4. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
5. Imports, In Physical Terms, By Country, 2012–2025
6. Imports, In Value Terms, By Country, 2012–2025
7. Import Prices, By Country, 2012–2025
8. Exports, In Physical Terms, By Country, 2012–2025
9. Exports, In Value Terms, By Country, 2012–2025
10. Export Prices, By Country, 2012–2025
LIST OF FIGURES
1. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
2. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Structure – Domestic Supply vs. Imports, in Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
4. Market Structure – Domestic Supply vs. Imports, in Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
5. Trade Balance, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
6. Trade Balance, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
7. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
8. Market Volume Forecast to 2035
9. Market Value Forecast to 2035
10. Market Size and Growth, By Product
11. Average Per Capita Consumption, By Product
12. Exports and Growth, By Product
13. Export Prices and Growth, By Product
14. Production Volume and Growth
15. Exports and Growth
16. Export Prices and Growth
17. Market Size and Growth
18. Per Capita Consumption
19. Imports and Growth
20. Import Prices
21. Production, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
22. Production, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
23. Imports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
24. Imports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
25. Imports, In Physical Terms, By Country, 2025
26. Imports, In Physical Terms, By Country, 2012–2025
27. Imports, In Value Terms, By Country, 2012–2025
28. Import Prices, By Country, 2012–2025
29. Exports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
30. Exports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
31. Exports, In Physical Terms, By Country, 2025
32. Exports, In Physical Terms, By Country, 2012–2025
33. Exports, In Value Terms, By Country, 2012–2025
34. Export Prices, By Country, 2012–2025

Mar 20, 2026

BioMarin Q4 2025 Revenue Beats Estimates but 2026 Guidance Concerns Investors

BioMarin's Q4 2025 revenue beat analyst forecasts, but weak full-year 2026 EPS guidance led to a stock decline, contrasting with sector stability.

Mar 18, 2026

Gilead Sciences Stock Outperforms Market Despite Business Quality Concerns

Gilead Sciences stock has significantly outperformed the market since March 2021, but an analysis reveals underlying business concerns including slow sales growth and declining financial metrics, suggesting potential better investment opportunities.

Mar 17, 2026

Gossamer Bio Reports Q4 2025 Financial Results

Gossamer Bio's Q4 2025 financial report shows a $47.2M loss but revenue of $13.8M beat analyst predictions, with full-year 2025 revenue at $48.5M.

Mar 16, 2026

Kyntra Bio Executives Detail 2025 Progress and Forward-Looking Strategy

Kyntra Bio executives detail 2025 progress on key cancer drug candidates and future strategy in a recent conference call, outlining clinical developments and forward-looking business statements.

Mar 16, 2026

Assertio Holdings Reviews 2025 Financial Results and Announces Strategic Pivot

Assertio Holdings reports on its 2025 financial performance, completes Rolvedon integration, and outlines a new strategy focusing on its core asset while moving away from its previous acquisition-based growth model.

Mar 13, 2026

Analysts Identify Divergent Paths for S&P 500 Healthcare and Consumer Stocks

A recent analysis reveals divergent prospects for S&P 500 companies, with healthcare firms IQVIA and Bristol-Myers Squibb facing specific headwinds, while consumer giant Coca-Cola is highlighted for attention.

G2 reviews

Teams rate IndexBox on G2

Verified reviewers highlight faster qualification, clearer collaboration, and stronger bid readiness.

High Performer

Regional Grid

High Performer Small-Business

Grid Report

Leader Small-Business

Grid Report

High Performer Mid-Market

Grid Report

Leader

Grid Report

Users Love Us

Milestone badge

★ ★ ★ ★ ★

5/5

Great for Market Insights and Analysis

“IndexBox is a solid source for trade and industrial market data — what I like best about it is how it aggregates official statistics.”